MS & Immune Disorders

In The Pipeline: Crossing the Blood-Brain Barrier to Fight Tumors

Zac Haughn, Senior Associate Editor

July/August 2014—Researchers have for the first time shown that an oncolytic virus, wild-type reovirus, infects and replicates in brain tumors following intravenous administration. Researchers…

Delayed MS Drugs Awaits Decision at FDA

Q&A with Kate Dawson, MD

May 2014—In March, Biogen learned the FDA would delay its decision on its peginterferon Beta-1a drug, also known as Plegridy, by three months when the agency announced it was extending…

Patients Report Delays in MS Diagnosis, High Interest in Oral Therapy

April 2014—Nationwide survey provides a snapshot of “MS in America.”

The MS Treatment Landscape: MSAA’s 2014 MS Research Update Provides Vital Information to Medical Professionals, Members of the MS Community

Susan Courtney and the Multiple Sclerosis Association of America

March 2014—New publication compiles the latest developments in MS research.

Recognizing and Responding to Comorbidities in MS

A Q&A with Ruth Ann Marrie, MD, PhD, FRCPC

March 2014—MS patients may be at increased risk for certain psychiatric and physical comorbidities. Neurologists can help identify and manage these conditions.

Iatrogenic Hypoglossal Nerve Palsy

Mark A. Fritz, MD, Bryan J. Kang, MD, Timothy P. Fox, MD, Nicky Bhatia, MD, and Steven M. Mandel, MD

January/February 2014—The hypoglossal nerve or twelfth cranial nerve (CNXII) innervates all of the intrinsic and extrinsic muscles of the ipsilateral tongue, except palatoglossus. Therefore, injuri…

Decreasing Progression, Increasing Function

Zac Haughn, Senior Associate Editor

September/October 2013—A small Phase I ALS study is getting big results with stem cell treatment.

A Treatment Within

A Q&A with Roland Martin, MD

July/August 2013—A small Phase I trial sees success using patients’ own altered blood cells to fight immune responses in MS. Is this the future of MS therapy?